Trial Profile
A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel-group Study to Assess the Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2017
Price :
$35
*
At a glance
- Drugs Selurampanel (Primary)
- Indications Muscle spasticity
- Focus Therapeutic Use
- Sponsors Novartis
- 21 Aug 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 01 Aug 2012 New trial record